Lactobacillus rhamnosus GG Usage in the Prevention of Gastrointestinal and Respiratory Tract Infections in Children with Gastroesophageal Reflux Disease Treated with Proton Pump Inhibitors: A Randomized Double-Blinded Placebo-Controlled Trial
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Proton-pump inhibitors (PPIs) are frequently used to treat gastroesophageal reflux disease (GERD) in children, but recent evidence suggests a potential association between PPI treatment and some types of infections. The aim of this study was to assess the effectiveness of Lactobacillus rhamnosus GG (LGG) for the prevention of gastrointestinal and respiratory tract infections in children with GERD treated with PPI (omeprazol). Methods: Children younger than 5 years with GERD were assigned by a computer-generated list to receive LGG (109 colony-forming units) or placebo, twice daily, concomitantly with PPI treatment for 4–6 weeks; they were followed up for 12 weeks after therapy. The primary outcome measures were the percentage of children with a minimum of one episode of respiratory tract infection and the percentage of children with a minimum of one episode of gastrointestinal infection during the study. Results: Of 61 randomized children, 59 patients (LGG n=30; placebo n=29, mean age 11.3 months) were analyzed. There was no significant difference found between the LGG and placebo groups, either for the proportion of children with at least one respiratory tract infection (22/30 vs. 25/29, respectively; relative risk [RR] 0.85, 95% confidence interval [CI] 0.66–1.10) or for the proportion of children with at least one gastrointestinal infection (9/30 vs. 9/29, respectively; RR 0.97, 95% CI 0.45–2.09). Conclusion: LGG was not effective in the prevention of infectious complications in children with GERD receiving PPI. Caution is needed in interpreting these results, as the study was terminated early due to slow subject recruitment.
Abstract
Purpose: Proton-pump inhibitors (PPIs) are frequently used to treat gastroesophageal reflux disease (GERD) in children, but recent evidence suggests a potential association between PPI treatment and some types of infections. The aim of this study was to assess the effectiveness of Lactobacillus rhamnosus GG (LGG) for the prevention of gastrointestinal and respiratory tract infections in children with GERD treated with PPI (omeprazol). Methods: Children younger than 5 years with GERD were assigned by a computer-generated list to receive LGG (109 colony-forming units) or placebo, twice daily, concomitantly with PPI treatment for 4–6 weeks; they were followed up for 12 weeks after therapy. The primary outcome measures were the percentage of children with a minimum of one episode of respiratory tract infection and the percentage of children with a minimum of one episode of gastrointestinal infection during the study. Results: Of 61 randomized children, 59 patients (LGG n=30; placebo n=29, mean age 11.3 months) were analyzed. There was no significant difference found between the LGG and placebo groups, either for the proportion of children with at least one respiratory tract infection (22/30 vs. 25/29, respectively; relative risk [RR] 0.85, 95% confidence interval [CI] 0.66–1.10) or for the proportion of children with at least one gastrointestinal infection (9/30 vs. 9/29, respectively; RR 0.97, 95% CI 0.45–2.09). Conclusion: LGG was not effective in the prevention of infectious complications in children with GERD receiving PPI. Caution is needed in interpreting these results, as the study was terminated early due to slow subject recruitment.
참고문헌 (28)
- Jaynes M, "The risks of long-term use of proton pump inhibitors : a critical review", Ther Adv Drug Saf, 10, pp.1~13 (2019)
- Jones NL, "Joint ESPGHAN", NASPGHAN guidelines for the management of Helicobacter pylori in children and adolescents(update 2016), 2017, pp.64, 991~1003
- Rosen R, "Pediatric gastroesophageal reflux clinical practice guidelines : joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition", J Pediatr Gastroenterol Nutr, 66, pp.516~554 (2018)
- Lucendo AJ, "Guidelines on eosinophilic esophagitis : evidence-based statements and recommendations for diagnosis and management in children and adults", United European Gastroenterol J, 5, pp.335~338 (2017)
- Hyams JS, "Functional disorders : children and adolescents", Gastroenterology, 150, pp.1456~1468 (2016)
- Gralnek IM, "Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage : European Society of Gastrointestinal Endoscopy(ESGE)Guideline", Endoscopy, 47, pp.a1~46 (2015)
- Bell JC, "Acid suppressants for managing gastro-oesophageal reflux and gastro-oesophageal reflux disease in infants : a national survey", Arch Dis Child, 103, pp.660~664 (2018)
- Ruigómez A, "Treatment patterns in paediatric patients with a new diagnosis of gastroesophageal reflux disease", Eur J Gastroenterol Hepatol, 23, pp.232~237 (2011)
- Barron JJ, "Proton pump inhibitor utilization patterns in infants", J Pediatr Gastroenterol Nutr, 45, pp.421~427 (2007)
- De Bruyne P, "Toxicity of long-term use of proton pump inhibitors in children", Arch Dis Child, 103, pp.78~82 (2018)
- Imhann F, "Proton pump inhibitors affect the gut microbiome", Gut, 65, pp.740~748 (2016)
- Rosen R, "Changes in gastric and lung microflora with acid suppression : acid suppression and bacterial growth", JAMA Pediatr, 168, pp.932~937 (2014)
- Bruno G, "Proton pump inhibitors and dysbiosis : Current knowledge and aspects to be clarified", World J Gastroenterol, 25, pp.2706~2719 (2019)
- Mishiro T, "Oral microbiome alterations of healthy volunteers with proton pump inhibitor", J Gastroenterol Hepatol, 33, pp.1059~1066 (2018)
- Oana Belei, "Is It Useful to Administer Probiotics Together With Proton Pump Inhibitors in Children With Gastroesophageal Reflux?", Journal of Neurogastroenterology and Motility (JNM), 24(1), pp.51~57 (2018), 대한소화기 기능성질환∙운동학회[DOI]
- Surendran Nair M, "Antivirulence properties of probiotics in combating microbial pathogenesis", Adv Appl Microbiol, 98, pp.1~29 (2017)
- Scott AM, "Probiotics for preventing acute otitis media in children", Cochrane Database Syst Rev, 6, pp.CD012941~ (2019)
- Laursen RP, "Probiotics for respiratory tract infections in children attending day care centers-a systematic review", Eur J Pediatr, 177, pp.979~994 (2018)
- Urbańska M, "Systematic review with meta-analysis : Lactobacillus reuteri DSM 17938 for diarrhoeal diseases in children", Aliment Pharmacol Ther, 43, pp.1025~1034 (2016)
- Hojsak I, "Probiotics for the prevention of nosocomial diarrhea in children", J Pediatr Gastroenterol Nutr, 66, pp.3~9 (2018)
- Szajewska H, "Probiotics for the prevention of antibiotic-associated diarrhea in children", J Pediatr Gastroenterol Nutr, 62, pp.495~506 (2016)
- Szajewska H, "Use of probiotics for management of acute gastroenteritis : a position paper by the ESPGHAN Working Group for Probiotics and Prebiotics", J Pediatr Gastroenterol Nutr, 58, pp.531~539 (2014)
- Sindhu KN, "Immune response and intestinal permeability in children with acute gastroenteritis treated with Lactobacillus rhamnosus GG : a randomized, double-blind, placebo-controlled trial", Clin Infect Dis, 58, pp.1107~1115 (2014)
- Canani RB, "Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children", Pediatrics, 117, pp.e817~20 (2006)
- Orenstein SR, "Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease", J Pediatr, 154, pp.514~520 (2009)
- Winter H, "Efficacy and safety of pantoprazole delayed-release granules for oral suspension in a placebo-controlled treatment-withdrawal study in infants 1-11 months old with symptomatic GERD", J Pediatr Gastroenterol Nutr, 50, pp.609~618 (2010)
- Writing Committee for the American Lung Association Asthma Clinical Research Centers, "Lansoprazole for children with poorly controlled asthma : a randomized controlled trial", JAMA, 307, pp.373~381 (2012)
- Moayyedi P, "Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin", Gastroenterology, 157, pp.682~691 (2019)